021-51111890
购物车（）
sales@molnova.cn
Labetuzumab
CAS No. 219649-07-7
Labetuzumab ( —— )
产品货号. M37694 CAS No. 219649-07-7
Labetuzumab 是一种人源化抗癌胚抗原 (CEA) 单克隆抗体，可抑制肿瘤生长并使人类髓样甲状腺癌异种细胞对 Dacarbazine 化疗敏感。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥4483 | 有现货 |
|
| 5MG | ￥5612 | 有现货 |
|
| 10MG | ￥8802 | 有现货 |
|
| 25MG | ￥12981 | 有现货 |
|
| 50MG | ￥17439 | 有现货 |
|
| 100MG | ￥22568 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Labetuzumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Labetuzumab 是一种人源化抗癌胚抗原 (CEA) 单克隆抗体，可抑制肿瘤生长并使人类髓样甲状腺癌异种细胞对 Dacarbazine 化疗敏感。
-
产品描述Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy.
-
体外实验——
-
体内实验Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo.Animal Model:Female nu/nu mice (6 to 8-week-old; inject TT cells).Dosage:0.5 mg/rat Administration:Intravenous injection; single (1 day post-tumor cell injection) Result:Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number219649-07-7
-
分子量145.1 kDa
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther. 2004 Dec;3(12):1559-64. ?
产品手册
关联产品
-
Carpachromene
Carpachromene could be a potential anti-inflammatory agent, it blocks protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in LPS-stimulated macrophages.Carpachromene shows significant α-glucosidase inhibitory activity.
-
7β,15α-Dihydroxy-3,1...
7β,15α-Dihydroxy-3,11,23-trioxolanosta-8,17(20)-dien-26-oic acid
-
A-K-R-R-R-L-S-S-L-R-...
A-K-R-R-R-L-S-S-L-R-A
